• http://www.snrs.org/?hosturl=2...c-celebrex obagi tretinoin cheap http://www.snrs.org/?hosturl=3...escription
  • donde puedo comprar viagra en tenerife http://discover.uga.edu/index....s-generico precio cialis y levitra http://discover.uga.edu/index....-la-cialis cialis comprar mexico
    what is furosemide tab 40 mg used for propecia pills price cipro buy online asda pharmacy fluconazole http://www.oerplatform.org/ind...one-dosage
  • clomid no prescription needed http://www.nhcadsv.org/sheaf.c...0mg-clomid paroxetine generic health can you buy clomid over the counter in south africa
  • Positive data announced for Reolysin in head and neck cancers

    Sun, Dec 23, 2012

    Oral Cancer News

    Source: www.empr.com
    Author: staff

    Oncolytics Biotech announced positive top line data in its double-blinded randomized Phase 3 clinical study examining Reolysin in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers. Reolysin is a proprietary formulation of the human reovirus.

    A first analysis compared the relative percentages of patients in the test and control arms with tumors that had either stabilized or exhibited shrinkage. For the purposes of this endpoint, the definition of tumor stabilization was restricted to 0% growth only. Of the 105 total patients with evaluable metastatic tumors, 86% (n=50) of those in the test arm of the study exhibited tumor stabilization or shrinkage, compared with 67% of patients (n=55) in the control arm. This was statistically significant, with a p-value of 0.025.

    A second analysis examined the magnitude of tumor response on a per patient basis using a comparison of percentage tumor shrinkage at six weeks in each patient with evaluable metastatic tumors. This analysis showed that Reolysin in combination with carboplatin and paclitaxel was statistically significantly better than carboplatin and paclitaxel alone at stabilizing or shrinking metastatic tumors, yielding a p-value of 0.03

    Print Friendly
    Be Sociable, Share!
    , , , , , ,

    Leave a Reply

    You must be logged in to post a comment.